European HTAs And Payers On How To Tackle The Evidence Problem
Executive Summary
European payers and health technology appraisal organizations have warned that their decision making is being increasingly hampered by evidence gaps. Some solutions may lie in the better use of existing mechanisms, such as scientific advice and managed entry agreements, while others could be introduced through the overhaul of the EU pharmaceutical legislation.
You may also be interested in...
Payers Set Out Radical Wishlist For Changes To EU Pharma Legislation
European payers have called for fast-track approval pathways and only limited use of conditional approvals in the upcoming reform of the EU’s pharmaceutical legislation. They also want to see data and market protection periods reduced to boost competition.
Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.
Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment
Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.